open access

Ahead of print
Review paper
Published online: 2022-12-16
Get Citation

Role of stereotactic body radiotherapy in the management of oligometastatic soft tissue and bone sarcomas

Konrad Zasadziński1, Mateusz Jacek Spałek12
DOI: 10.5603/NJO.a2022.0061
Affiliations
  1. Department of Radiotherapy I, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  2. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

open access

Ahead of print
Rare neoplasms in oncology
Published online: 2022-12-16

Abstract

Sarcomas are a highly heterogeneous group of rare malignancies. Historically, metastatic disease was considered incurable and was an indication for a palliative approach. Modern local therapies have led to a paradigm shift, making a long-term disease-free survival possible for selected groups of metastatic sarcoma patients. Oligometastatic and oligoprogressive disease constitute such indications. Although the administration of stereotactic radiation therapy (SBRT) for sarcoma metastases has been continuously rising over the past years, the evidence for such treatment is relatively scarce, lacking in larger prospective randomized clinical trials, and there is no consensus regarding strict indications, patient selection, and the time order of multimodal treatment. In this article, we discuss available clinical data regarding the efficacy and safety of SBRT in oligometastatic and oligoprogressive sarcoma, highlighting its indications in specific organ sites, as well as possible limitations of this treatment modality.

Abstract

Sarcomas are a highly heterogeneous group of rare malignancies. Historically, metastatic disease was considered incurable and was an indication for a palliative approach. Modern local therapies have led to a paradigm shift, making a long-term disease-free survival possible for selected groups of metastatic sarcoma patients. Oligometastatic and oligoprogressive disease constitute such indications. Although the administration of stereotactic radiation therapy (SBRT) for sarcoma metastases has been continuously rising over the past years, the evidence for such treatment is relatively scarce, lacking in larger prospective randomized clinical trials, and there is no consensus regarding strict indications, patient selection, and the time order of multimodal treatment. In this article, we discuss available clinical data regarding the efficacy and safety of SBRT in oligometastatic and oligoprogressive sarcoma, highlighting its indications in specific organ sites, as well as possible limitations of this treatment modality.

Get Citation

Keywords

stereotactic body radiotherapy; sarcoma; metastases; hypofractionation; radiotherapy

About this article
Title

Role of stereotactic body radiotherapy in the management of oligometastatic soft tissue and bone sarcomas

Journal

Nowotwory. Journal of Oncology

Issue

Ahead of print

Article type

Review paper

Published online

2022-12-16

Page views

24

Article views/downloads

18

DOI

10.5603/NJO.a2022.0061

Keywords

stereotactic body radiotherapy
sarcoma
metastases
hypofractionation
radiotherapy

Authors

Konrad Zasadziński
Mateusz Jacek Spałek

References (35)
  1. Spałek MJ, Kozak K, Czarnecka AM, et al. Neoadjuvant Treatment Options in Soft Tissue Sarcomas. Cancers (Basel). 2020; 12(8).
  2. Gronchi A, Miah AB, Dei Tos AP, et al. ESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: clinicalguidelines@esmo.org. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(11): 1348–1365.
  3. Strauss SJ, Frezza AM, Abecassis N, et al. ESMO Guidelines Committee, EURACAN, GENTURIS and ERN PaedCan. Electronic address: clinicalguidelines@esmo.org. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(12): 1520–1536.
  4. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13(1): 8–10.
  5. Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020; 148: 157–166.
  6. Spałek M, Borkowska A. Current advances in radiotherapy for soft tissue sarcomas. Nowotwory. Journal of Oncology. 2020; 70(6): 288–295.
  7. Patel PH, Palma D, McDonald F, et al. The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively? Clin Oncol (R Coll Radiol). 2019; 31(12): 824–833.
  8. Spałek MJ. Leczenie pembrolizumabem skojarzonym z radioterapią stereotaktyczną w przypadku zaawansowanego czerniaka skóry głowy. Onkologia w Praktyce Klinicznej - Edukacja. 2021; 7(Supl. B): 31–36.
  9. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012; 7(12): 1807–1814.
  10. Weykamp F, König L, Seidensaal K, et al. Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer. Front Oncol. 2020; 10: 987.
  11. Ost P, Jereczek-Fossa BA, As NV, et al. Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis. Eur Urol. 2016; 69(1): 9–12.
  12. Yamashita H, Niibe Y, Yamamoto T, et al. Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases. Jpn J Clin Oncol. 2016; 46(7): 687–691.
  13. Cheung P. Stereotactic body radiotherapy for oligoprogressive cancer. Br J Radiol. 2016; 89(1066): 20160251.
  14. Guckenberger M, Lievens Y, Bouma A, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21(1): e18–e28.
  15. Spałek MJ, Teterycz P, Borkowska A, et al. Stereotactic radiotherapy for soft tissue and bone sarcomas: real-world evidence. Ther Adv Med Oncol. 2022; 14: 17588359211070646.
  16. Pennacchioli E, Tosti G, Barberis M, et al. Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread? Clin Exp Metastasis. 2012; 29(7): 757–773.
  17. Marulli G, Mammana M, Comacchio G, et al. Survival and prognostic factors following pulmonary metastasectomy for sarcoma. J Thorac Dis. 2017; 9(Suppl 12): S1305–S1315.
  18. Chang J, Mehran R, Feng L, et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021; 22(10): 1448–1457.
  19. Dhakal S, Corbin KS, Milano MT, et al. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival. Int J Radiat Oncol Biol Phys. 2012; 82(2): 940–945.
  20. Baumann BC, Nagda SN, Kolker JD, et al. Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection. J Surg Oncol. 2016; 114(1): 65–69.
  21. Baumann BC, Bernstein KD, DeLaney TF, et al. Multi-institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity. J Surg Oncol. 2020; 122(5): 877–883.
  22. Mehta N, Selch M, Wang PC, et al. Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma. Sarcoma. 2013; 2013: 360214.
  23. Navarria P, Ascolese AM, Cozzi L, et al. Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. Eur J Cancer. 2015; 51(5): 668–674.
  24. Frakulli R, Salvi F, Balestrini D, et al. Stereotactic Radiotherapy in the Treatment of Lung Metastases from Bone and Soft-tissue Sarcomas. Anticancer Res. 2015; 35(10): 5581–5586.
  25. Soyfer V, Corn BW, Shtraus N, et al. Single-institution Experience of SBRT for Lung Metastases in Sarcoma Patients. Am J Clin Oncol. 2017; 40(1): 83–85.
  26. Lindsay AD, Haupt EE, Chan CM, et al. Treatment of Sarcoma Lung Metastases with Stereotactic Body Radiotherapy. Sarcoma. 2018; 2018: 9132359.
  27. Navarria P, Baldaccini D, Clerici E, et al. Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study. Int J Radiat Oncol Biol Phys. 2022; 114(4): 762–770.
  28. Tanadini-Lang S, Rieber J, Filippi AR, et al. Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiother Oncol. 2017; 123(2): 182–188.
  29. Stragliotto CL, Karlsson K, Lax I, et al. A retrospective study of SBRT of metastases in patients with primary sarcoma. Med Oncol. 2012; 29(5): 3431–3439.
  30. Brown LC, Lester RA, Grams MP, et al. Stereotactic body radiotherapy for metastatic and recurrent ewing sarcoma and osteosarcoma. Sarcoma. 2014; 2014: 418270.
  31. Koseła-Paterczyk H, Spałek M, Borkowska A, et al. Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall: Results of a Single-Arm Prospective Clinical Trial. J Clin Med. 2020; 9(8).
  32. Zając AE, Kopeć S, Szostakowski B, et al. Chondrosarcoma-from Molecular Pathology to Novel Therapies. Cancers (Basel). 2021; 13(10).
  33. Hindawi. Surmounting Chemotherapy and Radioresistance in Chondrosarcoma: Molecular Mechanisms and Therapeutic Targets n.d. https://www.hindawi.com/journals/sarcoma/2011/381564/ (14.09.2022).
  34. Yang GQ, Yuan ZM, Welsh E, et al. Intrinsic Radiosensitivity Index Differences of Sarcoma and the Potential for Genome-Adjusted Radiation Dosing. Int J Radiat Oncol Biol Phys. 2019; 105(1): E812.
  35. European Organisation for Research and Treatment of Cancer - EORTC. Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial. clinicaltrials.gov. 2021.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl